Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model

Abstract Background The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effective treatment strategy for this refractory disease....

Full description

Bibliographic Details
Main Authors: Md. Hafiz Uddin, Mohammad Najeeb Al‐Hallak, Husain Yar Khan, Amro Aboukameel, Yiwei Li, Sahar F. Bannoura, Gregory Dyson, Seongho Kim, Yosef Mzannar, Ibrahim Azar, Tanya Odisho, Amr Mohamed, Yosef Landesman, Steve Kim, Rafic Beydoun, Ramzi M. Mohammad, Philip A. Philip, Anthony F. Shields, Asfar S. Azmi
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Clinical and Translational Medicine
Subjects:
digital spatial profiling
gemcitabine
KPC mouse model
nab‐paclitaxel
pancreatic cancer
selinexor
Online Access:https://doi.org/10.1002/ctm2.1513

Internet

https://doi.org/10.1002/ctm2.1513

Similar Items